
Opinion|Videos|August 30, 2024
Biomarkers as Tools in Management of Type 2 Inflammation
Author(s)Reynold A. Panettieri Jr, MD
An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.
Advertisement
Episodes in this series

- What biomarkers can reliably assess the presence of type 2 inflammation as a contributing factor in asthma or COPD?
- How can absolute eosinophil count specifically be used as a tool in this population for regimen selection? Does this biomarker have a role in predicting treatment response or patient outcomes?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement



